Gilead Sciences PM onboarding first 90 days what to expect 2026

Title: Gilead Sciences PM Onboarding First 90 Days What to Expect 2026

TL;DR

The first 90 days as a product manager at Gilead Sciences are not about launching features—they’re about earning trust, mapping decision loops, and surviving the clinical-commercial handoff. You will attend 12 to 15 cross-functional alignment meetings in your first month, most of which have no agenda. The real evaluation is not your roadmap, but whether commercial ops trusts your judgment. Most new PMs fail by speaking like a tech PM; the ones who succeed learn to speak like a clinical operations proxy.

Who This Is For

This is for product managers joining Gilead Sciences in 2026 in roles such as Associate Product Manager, Product Manager – HIV, or Oncology Digital Solutions, especially those transitioning from tech or consumer tech. You likely have 3–7 years of PM experience, possibly at a startup or FAANG, but zero exposure to biopharma regulatory constraints. You care about impact, not just velocity. You need to know who holds influence, not just who holds title.

What does the first week of onboarding look like for a PM at Gilead?

The first week is administrative purgatory disguised as orientation. You’ll complete 8 hours of GxP compliance training, sit through 3 mandatory HR sessions, and receive a badge that doesn’t grant access to the clinical data warehouse. The real onboarding begins when your manager forwards you the Q3 brand plan for your therapy area—usually two days late, with no context.

Not every meeting is documented, but every decision is tracked. The problem isn’t information access—it’s signal detection. In a Q3 2024 debrief, a hiring manager rejected a candidate’s onboarding plan because it focused on “customer interviews” instead of “understanding the FDA commitments in the latest BLA amendment.” At Gilead, your product isn’t what users want—it’s what the label allows.

You’ll be assigned a “buddy,” usually a tenured PM in a different franchise, who will not tell you how the medical affairs escalation path works. That knowledge is earned by surviving your first payer access dispute. Your first deliverable isn’t a PRD—it’s a stakeholder influence map due in week three, listing who can block a launch, not just who attends the meeting.

How does Gilead’s PM role differ from tech companies in the first 90 days?

Gilead PMs don’t own roadmaps—they steward compliance-bound brand plans. The first 90 days are not about shipping; they’re about not breaking anything. In tech, velocity is rewarded. At Gilead, a single misstep in communication with medical affairs can trigger a regulatory inquiry. The difference isn’t culture—it’s liability.

Not innovation, but alignment. A former Amazon PM hired in 2023 was asked to revise her Q1 initiative three times because it implied off-label promotion potential. The phrase “user-driven feature enhancement” was flagged by compliance. At Gilead, you don’t say “users”—you say “healthcare providers” or “patients within indication.”

The decision-making model is not product-led—it’s committee-ensured. You will attend the Therapy Area Strategy Forum in week five, where your input will be summarized by a medical director who speaks last. Influence is not claimed; it’s granted after you’ve demonstrated understanding of risk tradeoffs. One PM’s proposal was delayed six months because she referenced real-world data without pre-clearing it with epidemiology.

Good PMs document assumptions. Great PMs document who signed off on them.

What are the key milestones for a PM in the first 90 days at Gilead?

By day 30, you must deliver a therapy area landscape brief that passes medical and legal review. This is not a market analysis—it’s a risk-mitigated narrative. One candidate in 2025 failed their 30-day check-in because they cited a payer formulary change as an “opportunity” rather than a “coverage access variance.”

By day 60, you lead your first cross-functional tactics meeting. The agenda must be pre-cleared by commercial ops and medical affairs. The real milestone isn’t running the meeting—it’s ensuring no one escalates afterward. In a Q2 2024 HC meeting, a PM was told they were “not ready for prime time” because their meeting generated two unresolved compliance questions.

By day 90, you present your Q4 contribution plan to the franchise head. It must include: one patient access initiative, one payer engagement tactic, and one digital touchpoint aligned to Phase IV study objectives. The presentation is not evaluated on creativity—it’s evaluated on whether compliance and medical gave silent approval.

Not delivery, but containment. The 90-day bar isn’t “did you achieve goals?”—it’s “did you create new risks?”

Who are the critical stakeholders a new PM must align with in the first 90 days?

You must build working relationships with six non-negotiable roles: Medical Affairs Lead, Payer Strategy Director, Regulatory Compliance Officer, Epidemiology Liaison, Commercial Ops Manager, and Patient Advocacy Lead. The hiring manager in a 2024 HC discussion stated flatly: “If the Medical Affairs lead hasn’t vouched for you by day 45, the 90-day review will be a formality.”

Not networking, but pattern recognition. These stakeholders do not respond to “weekly sync” requests. They respond to demonstrated understanding of their constraints. One PM succeeded by reviewing the last three FDA warning letters relevant to their franchise and referencing them in a compliance meeting—without being asked.

The Payer Strategy Director controls access data but won’t share it unless you frame requests around formulary positioning, not user behavior. The Epidemiology Liaison will ignore you unless you cite their published studies. The Patient Advocacy Lead cares not about features, but about disease burden narratives.

In a 2023 debrief, a candidate was downgraded because their stakeholder map listed “VP of Digital” as primary, but omitted the Pharmacovigilance contact. At Gilead, safety trumps scale.

How is performance evaluated for a PM during onboarding at Gilead?

Performance is evaluated on three silent signals: whether other functions initiate communication with you, whether your documents require zero rework by legal, and whether your name appears in the “no objections” section of the brand council minutes. No one tells you this. You learn it when your manager says, “They’re starting to include you in the pre-reads.”

Not output, but integration. In a 2024 HC meeting, a hiring manager said, “She hasn’t launched anything, but medical asked her to co-lead the payer dossier update—that’s the signal.” The real KPI is not completion—it’s co-ownership.

You will have a formal 30-60-90 plan, but it’s ceremonial. What matters is whether you anticipated the payer access delay in Q3 and adjusted messaging before the commercial team did. One PM was fast-tracked because they revised a patient support program FAQ before a CMS policy change took effect—without being prompted.

The annual review cycle starts in week eight. Your name will be mentioned in franchise head updates. If those mentions are defensive (“we’re still onboarding them”), you’re behind. If they’re assumptive (“as Sarah outlined”), you’re on track.

What should you prepare before starting as a PM at Gilead?

Study the latest FDA labels for your therapy area. Memorize the boxed warnings. Read the most recent 10-K section on pipeline risks. Understand the difference between a Risk Evaluation and Mitigation Strategy (REMS) and a standard label restriction. Arrive knowing why you can’t “A/B test” a patient support message.

Not generic PM prep, but domain-specific fluency. In a 2025 hiring committee meeting, a candidate was rejected because they couldn’t explain how Gilead’s Veklury label differs from Merck’s Lagevrio in outpatient use. The hiring manager said, “He knew PM frameworks but not our regulatory posture.”

You must also map the organizational chart beyond your function. Know who leads Global Safety, who sits on the Brand Governance Committee, and who controls the budget for patient services. These are not public org charts—they’re inferred from meeting invites and document approvers.

One incoming PM reviewed 18 months of press releases and earnings call transcripts. During onboarding, they referenced a cost-of-illness study mentioned by the CFO in Q4 2024. The franchise head noted it in their 30-day feedback: “Shows initiative in understanding business context.”

Work through a structured preparation system (the PM Interview Playbook covers biopharma stakeholder alignment with real debrief examples from Gilead, Amgen, and J&J).

Preparation Checklist

Complete all pre-onboarding HR and compliance modules before Day 1
Map the latest FDA label and REMS requirements for your product
Identify and review the last three brand council decisions in your franchise
Draft a stakeholder influence map with escalation paths for medical, legal, and compliance
Schedule informal 1:1s with Medical Affairs, Payer Strategy, and Patient Advocacy contacts
Review 4 quarters of earnings calls and investor presentations for strategic themes
Work through a structured preparation system (the PM Interview Playbook covers biopharma stakeholder alignment with real debrief examples from Gilead, Amgen, and J&J)

Mistakes to Avoid

BAD: Sending a product idea to digital marketing without pre-clearing with medical affairs. Result: The initiative is flagged, you’re asked to attend a compliance retraining, and your name is added to the “requires co-sign” list.

GOOD: Drafting the concept, then walking it verbally to the medical liaison before documentation. You hear “we could support that if we frame it around adherence” and adjust. No formal approval needed—just alignment.

BAD: Presenting a roadmap with user research quotes. Result: Legal raises concerns about implied off-label use. Medical affairs disavows the data. Your credibility drops.

GOOD: Framing insights as “healthcare provider feedback collected through approved channels” and citing internal advisory board summaries. You’re seen as careful, not cautious.

BAD: Focusing on app engagement metrics in your 90-day review. Result: The franchise head interrupts: “We care about patient access, not daily active users.” The meeting ends early.

GOOD: Leading with patient initiation rates, payer coverage changes, and safety case volume. You speak the language of biopharma outcomes.

FAQ

What does a typical day look like for a PM at Gilead in the first 90 days?

You spend 60% of your time in meetings without agendas, 20% revising documents for compliance, and 20% chasing approvals. The work isn’t in doing—it’s in navigating. Your calendar fills with “pre-read alignment” and “risk review” sessions. You don’t run projects—you shepherd them through governance. Success isn’t measured by tasks checked, but by escalations avoided.

Is the PM role at Gilead more strategic or executional in the first 90 days?

It is neither. It is observational. You are expected to absorb decision frameworks, not drive outcomes. The first 90 days are a shadow period in disguise. Strategic contribution comes only after you’ve demonstrated adherence to process. Execution is owned by commercial ops. Your job is to understand where risk lives—and stay upstream of it.

How much autonomy does a new PM have at Gilead?

Almost none. Every external-facing message, digital asset, and customer interaction must be pre-approved by legal, medical, and compliance. Your autonomy lies in how you frame requests, not what you build. The PM with influence isn’t the one who pushes fastest—it’s the one who anticipates objections and removes them before the meeting starts.

Ready to build a real interview prep system?

Get the full PM Interview Prep System →

The book is also available on Amazon Kindle.